Merck KGaA, Darmstadt, Germany, Announces Research Collaboration with Domain Therapeutics in Immuno-Oncology

Merck KGaA, Darmstadt, Germany, a leading science and technology company which operates its biopharmaceutical business in the US and Canada as EMD Serono, today announced it has entered into a collaboration and licensing agreement with Domain Therapeutics, Strasbourg, France, to explore the potential of adenosine inhibition in the development of novel immuno-oncology agents. This collaboration strengthens our combination strategy in immuno-oncology, and underscores Merck KGaA, Darmstadt, Germany’s sciencedriven approach to discovering and developing novel compounds through both internal capabilities and external collaborations.